• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在人源化小鼠中使用肉瘤细胞同种异体移植评估I-JS001用于hPD1免疫PET成像。

Evaluation of I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice.

作者信息

Huang Haifeng, Zhu Hua, Xie Quan, Tian Xiaobin, Yang Xianteng, Feng Fan, Jiang Qiyu, Sheng Xinan, Yang Zhi

机构信息

Guizhou University School of Medicine, Guizhou University, Guiyang 550025, China.

Department of Orthopaedics, Guizhou Provincial People's Hospital, Guiyang 550002, China.

出版信息

Acta Pharm Sin B. 2020 Jul;10(7):1321-1330. doi: 10.1016/j.apsb.2020.02.004. Epub 2020 Feb 19.

DOI:10.1016/j.apsb.2020.02.004
PMID:32874831
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7452040/
Abstract

JS001 (toripalimab) is a humanized IgG monoclonal antibody which strongly inhibits programmed cell death protein 1 (PD1). In this study, we used a different iodine isotype (I) to label JS001 probes to target the human PD1 (hPD1) antigen. , the half maximal effective concentration (EC) value of I-JS001 did not significantly differ from that of JS001. The uptake of I-JS001 by activated T cells was 5.63 times higher than that by nonactivated T cells after 2 h of incubation. The binding affinity of I-JS001 to T cells of different lineages after phytohemagglutinin (PHA) stimulation reached 4.26 nmol/L. Humanized C57BL/6 mice bearing mouse sarcoma S180 cell tumors were validated for immuno-positron emission tomography (immuno-PET) imaging. Pathological staining was used to assess the expression of PD1 in tumor tissues. The homologous Ihuman IgG (IhIgG) group or blocking group was used as a control group. Immuno-PET imaging showed that the uptake in the tumor area of the I-JS001 group at different time points was significantly higher than that of the blocking group or the I-hIgG group in the humanized mouse model. Taken together, these results suggest that this radiotracer has potential for noninvasive monitoring and directing tumor-specific personalized immunotherapy in PD1-positive tumors.

摘要

JS001(托瑞帕利单抗)是一种人源化IgG单克隆抗体,可强烈抑制程序性细胞死亡蛋白1(PD1)。在本研究中,我们使用不同的碘同位素(I)标记JS001探针,以靶向人PD1(hPD1)抗原。I-JS001的半数最大有效浓度(EC)值与JS001的该值无显著差异。孵育2小时后,活化T细胞对I-JS001的摄取比未活化T细胞高5.63倍。I-JS001对植物血凝素(PHA)刺激后不同谱系T细胞的结合亲和力达到4.26 nmol/L。对携带小鼠肉瘤S180细胞肿瘤的人源化C57BL/6小鼠进行免疫正电子发射断层扫描(immuno-PET)成像验证。采用病理染色评估肿瘤组织中PD1的表达。以同源人IgG(IhIgG)组或阻断组作为对照组。免疫PET成像显示,在人源化小鼠模型中,I-JS001组在不同时间点的肿瘤区域摄取显著高于阻断组或I-hIgG组。综上所述,这些结果表明这种放射性示踪剂在无创监测和指导PD1阳性肿瘤的肿瘤特异性个性化免疫治疗方面具有潜力。

相似文献

1
Evaluation of I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice.在人源化小鼠中使用肉瘤细胞同种异体移植评估I-JS001用于hPD1免疫PET成像。
Acta Pharm Sin B. 2020 Jul;10(7):1321-1330. doi: 10.1016/j.apsb.2020.02.004. Epub 2020 Feb 19.
2
Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice.采用人源化小鼠对靶向 hPD1/CTLA4 的双特异性抗体进行临床前影像学评估。
Biomed Pharmacother. 2024 Jun;175:116669. doi: 10.1016/j.biopha.2024.116669. Epub 2024 Apr 26.
3
Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study.使用 124I 标记的拓益(特瑞普利单抗注射液)对癌症患者程序性死亡受体 1 表达进行正电子发射断层扫描成像:一项初步临床转化研究。
Clin Nucl Med. 2021 May 1;46(5):382-388. doi: 10.1097/RLU.0000000000003520.
4
Construction and Preclinical Evaluation of I/I-Labeled Antibody Targeting T Cell Immunoglobulin and Mucin Domain-3.构建并临床前评估 I/I 标记的针对 T 细胞免疫球蛋白和黏蛋白结构域-3 的抗体。
Mol Pharm. 2024 Feb 5;21(2):944-956. doi: 10.1021/acs.molpharmaceut.3c01046. Epub 2024 Jan 25.
5
Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.用于人体免疫检查点成像的实用免疫正电子发射断层显像剂设计考量
J Nucl Med. 2017 Apr;58(4):538-546. doi: 10.2967/jnumed.116.177659. Epub 2016 Dec 15.
6
Development of Tc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murine.Tc 标记 JS001 抗体用于在体检测小鼠 PD-1 分布
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2178-2181. doi: 10.1016/j.bmcl.2019.06.019. Epub 2019 Jun 17.
7
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.Sym021,一种有前景的抗 PD1 临床候选抗体,源自一个新的鸡抗体发现平台。
MAbs. 2019 May/Jun;11(4):666-680. doi: 10.1080/19420862.2019.1596514. Epub 2019 May 3.
8
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.抗 PD-1 抗体 JS001 治疗晚期黑色素瘤或泌尿系统癌症患者的安全性和临床活性。
J Hematol Oncol. 2019 Jan 14;12(1):7. doi: 10.1186/s13045-018-0693-2.
9
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.外周血 PD1 阳性 CD4 T 淋巴细胞计数可预测接受免疫检查点抑制剂治疗的非小细胞肺癌患者的无进展生存期。
Anticancer Res. 2019 Dec;39(12):6887-6893. doi: 10.21873/anticanres.13908.
10
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma.动态肿瘤特异性 MHC-II 免疫 PET 预测黑色素瘤检查点抑制剂免疫治疗的疗效。
J Nucl Med. 2022 Nov;63(11):1708-1714. doi: 10.2967/jnumed.121.263151. Epub 2022 Feb 24.

引用本文的文献

1
Development of selective ssDNA micro-probe for PD1 detection as a novel strategy for cancer imaging.开发用于 PD1 检测的选择性 ssDNA 微探针作为癌症成像的新策略。
Sci Rep. 2024 Nov 19;14(1):28652. doi: 10.1038/s41598-024-74891-7.
2
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.探索PD-1/PD-L1成像示踪剂领域:从挑战到机遇
Front Med (Lausanne). 2024 Jun 7;11:1401515. doi: 10.3389/fmed.2024.1401515. eCollection 2024.
3
Development of Small HN Linked Radionuclide Iodine-125 for Nanocarrier Image Tracing in Mouse Model.

本文引用的文献

1
Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting.通过酵母展示技术和互补决定区(CDR)移植提高全人源抗白细胞介素-17A抗体的亲和力和热稳定性。
Acta Pharm Sin B. 2019 Sep;9(5):960-972. doi: 10.1016/j.apsb.2019.02.007. Epub 2019 Feb 22.
2
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.阿昔替尼联合特泊替尼(一种针对程序性死亡受体-1 的人源化免疫球蛋白 G 单克隆抗体)治疗转移性黏膜黑色素瘤患者的开放标签 Ib 期临床试验。
J Clin Oncol. 2019 Nov 10;37(32):2987-2999. doi: 10.1200/JCO.19.00210. Epub 2019 Aug 12.
3
发展小 HN 连接放射性碘-125 纳米载体在小鼠模型中的示踪成像。
Int J Nanomedicine. 2024 Feb 23;19:1909-1922. doi: 10.2147/IJN.S446564. eCollection 2024.
4
I-labeled anti-CD147 antibody for noninvasive detection of CD147-positive pan-cancers: construction and preclinical studies.I 标记的抗 CD147 抗体用于非侵入性检测 CD147 阳性的泛癌:构建和临床前研究。
Acta Pharmacol Sin. 2024 Feb;45(2):436-448. doi: 10.1038/s41401-023-01162-y. Epub 2023 Sep 25.
5
Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy.正电子发射断层扫描分子成像监测免疫检查点抑制剂治疗的抗肿瘤全身反应。
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1671-1688. doi: 10.1007/s00259-022-06084-1. Epub 2023 Jan 9.
6
Imaging Hallmarks of Sarcoma Progression Via X-ray Computed Tomography: Beholding the Flower of Evil.通过X射线计算机断层扫描观察肉瘤进展的影像学特征:凝视邪恶之花。
Cancers (Basel). 2022 Oct 19;14(20):5112. doi: 10.3390/cancers14205112.
7
Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?软组织肉瘤的虚拟活检。我们距离成功还有多远?
Front Oncol. 2022 Jul 1;12:892620. doi: 10.3389/fonc.2022.892620. eCollection 2022.
8
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.正电子发射断层扫描和单光子发射计算机断层扫描用放射性药物:过去十年的文献综述。
Int J Mol Sci. 2022 Apr 30;23(9):5023. doi: 10.3390/ijms23095023.
9
Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China.特瑞普利单抗:中国首款国产抗肿瘤 PD-1 抗体。
Front Immunol. 2022 Jan 12;12:730666. doi: 10.3389/fimmu.2021.730666. eCollection 2021.
10
Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma.新型难溶性药物安罗替尼纳米晶注射液及其对肝癌的抗肿瘤作用
Front Oncol. 2021 Dec 2;11:777356. doi: 10.3389/fonc.2021.777356. eCollection 2021.
Development of Tc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murine.Tc 标记 JS001 抗体用于在体检测小鼠 PD-1 分布
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2178-2181. doi: 10.1016/j.bmcl.2019.06.019. Epub 2019 Jun 17.
4
Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy.肺癌治疗中的生物疗法:利用我们的免疫系统作为盟友来战胜恶性肿瘤。
Expert Opin Biol Ther. 2019 May;19(5):457-467. doi: 10.1080/14712598.2019.1582635. Epub 2019 Feb 27.
5
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.不断发展的免疫检查点抑制剂治疗生物标志物。
Nat Rev Cancer. 2019 Mar;19(3):133-150. doi: 10.1038/s41568-019-0116-x.
6
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.抗 PD-1 抗体 JS001 治疗晚期黑色素瘤或泌尿系统癌症患者的安全性和临床活性。
J Hematol Oncol. 2019 Jan 14;12(1):7. doi: 10.1186/s13045-018-0693-2.
7
[Clinical Development of Immunotherapy for Small Cell Lung Cancer].[小细胞肺癌免疫治疗的临床进展]
Zhongguo Fei Ai Za Zhi. 2018 Dec 20;21(12):918-923. doi: 10.3779/j.issn.1009-3419.2018.12.10.
8
Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy.恩考芬尼/比美替尼用于治疗BRAF突变的晚期、不可切除或转移性黑色素瘤:设计、研发及在治疗中的潜在地位
Onco Targets Ther. 2018 Dec 14;11:9081-9089. doi: 10.2147/OTT.S171693. eCollection 2018.
9
Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?放疗与免疫治疗联合治疗肺癌:正常组织毒性改变是否会带来限制?
Int J Mol Sci. 2018 Dec 21;20(1):24. doi: 10.3390/ijms20010024.
10
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.在非小细胞肺癌的免疫检查点阻断期间肿瘤和免疫反应的动力学
Cancer Res. 2019 Mar 15;79(6):1214-1225. doi: 10.1158/0008-5472.CAN-18-1127. Epub 2018 Dec 12.